Low-dose Interleukin-2 in the Treatment of Autoimmune Disease | touchONCOLOGY - 0 views
www.touchoncology.com/...2-treatment-autoimmune-disease
cancer autoimmune disease Tregs Treg cells Treg immune system disease IL-2
shared by Nathan Goodyear on 04 Apr 18
- No Cached
Amol kashikar liked it
-
affect approximately 5 to 8 % of the US population
-
Type 1 diabetes (T1D), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) account for the majority of the patients with autoimmune diseases
- ...9 more annotations...
-
Autoimmune diseases are characterized by a breakdown of mechanisms that allow the immune system to distinguish between self and nonself and maintain immunologic self-tolerance
-
Several subtypes of Tregs exist, the most well studied being CD4+ cells that express high-level CD25 and the transcription factor forkhead box P3 (FOXP3)
-
In clinical studies, decreased levels of circulating CD25+CD4+ T cells have been reported in patients with autoimmune disease
-
These data have led to the hypothesis that augmentation of Tregs may be a useful therapeutic strategy in autoimmune disease
-
Treg augmentation has resulted in clinical improvements in numerous animal models of autoimmune diseases
-
the administration of in vitro expanded CD4+CD25highCD127-Tregs has been found to be safe and may help to preserve β-cell function in children with T1D
-
Great article. Immune dysfunction plays role in autoimmune disease and cancer. Treg cells sit at the center of autoimmunity. This artice highlights the different uses: low dose IL2 therapy to augment Tregs and reduce autoinflammation and high dose IL2 to augment Treg cells in the fight against cancer.